Semaglutide bụ polypeptide nke ndị dọkịta nyere iwu maka ọgwụgwọ ụdị ọrịa shuga 2.FDA akwadola iji Novo Nordisk's Ozempic na Rybelsus dị ka ịgba ọgwụ otu ugboro kwa izu ma ọ bụ dị ka mbadamba nkume, n'otu n'otu.Otu ugboro kwa izu ntụtụ nke semaglutide nwere akara aha Wegovy ka akwadoro n'oge na-adịbeghị anya dị ka ọgwụgwọ mbelata ibu.
Nnyocha ọhụrụ ewepụtara na European Congress on Obesity nke afọ a (ECO2023, Dublin, 17-20 May) na-egosi na semaglutide nke oke ibu na-arụ ọrụ maka oke ibu na multicenter, 1 afọ n'ezie ọmụmụ ụwa.Ọmụmụ ihe bụ Dr Andres Acosta na Dr Wissam Ghusn, Precision Medicine for Obesity Programme na Mayo Clinic, Rochester, MN, USA na ndị ọrụ ibe ya.
Semaglutide, glucagon-dị ka peptide-1 (GLP-1) agonist nnabata, bụ ọgwụ mgbochi oke ibu nke FDA kwadoro na nso nso a.O gosiputara nsonaazụ ọnwụ dị oke mkpa n'ọtụtụ nnwale ụlọ ọgwụ na-adịte aka na obere oge n'ezie n'ụwa.Otú ọ dị, a maara ntakịrị ihe gbasara mbelata ibu na usoro metabolic pụta na ọmụmụ ihe dị n'etiti etiti oge.N'ime ọmụmụ ihe a, ndị na-ede akwụkwọ nyochara nsonaazụ ọnwụ dị arọ metụtara semaglutide na ndị ọrịa nwere oke ibu na oke ibu na-enweghị ụdị ọrịa shuga 2 (T2DM) na nsonye 1 afọ.
Ha mere nyochaghachi, multicentre (Mayo Clinic Hospitals: Minnesota, Arizona, na Florida) nchịkọta data na ojiji nke semaglutide maka ọgwụgwọ oke ibu.Ha gụnyere ndị ọrịa nwere nrịbama ahụ (BMI) ≥27 kg / m2 (oke ibu na ụdị BMI niile dị elu) bụ ndị a na-enye ọgwụ injections semaglutide kwa izu (doses 0.25, 0.5, 1, 1.7, 2, 2.4mg; agbanyeghị na ọtụtụ nọ na ya. Oke dose 2.4mg).Ha wepụrụ ndị ọrịa na-aṅụ ọgwụ ndị ọzọ maka oke ibu, ndị nwere akụkọ ihe mere eme nke ịwa ahụ oke ibu, ndị nwere ọrịa kansa, na ndị dị ime.
Ebe njedebe bụ isi bụ mkpokọta mbelata ibu ahụ (TBWL%) na otu afọ.Isi njedebe nke abụọ gụnyere ọnụọgụ nke ndị ọrịa na-enweta ≥5%, ≥10%, ≥15%, na ≥20% TBWL%, mgbanwe na usoro metabolic na nke obi (ọbara mgbali elu, HbA1c [haemoglobin glycated, ihe na-achịkwa shuga ọbara]). Glucose na-ebu ọnụ na abụba ọbara), TBWL% nke ndị ọrịa nwere na ndị na-enweghị T2DM, yana ugboro ole mmetụta dị n'ime afọ mbụ nke ọgwụgwọ.
Ngụkọta nke ndị ọrịa 305 gụnyere na nyocha (73% nwanyị, pụtara afọ 49, 92% ọcha, pụtara BMI 41, 26% na T2DM) .E gosipụtara njirimara ntọala na nkọwa nlekọta nlekọta ịdị arọ na tebụl 1 zuru oke.N'ime otu ahụ dum, ihe pụtara TBWL% bụ 13.4% na 1 afọ (maka ndị ọrịa 110 nwere data ibu na 1 afọ).Ndị ọrịa nwere T2DM nwere obere TBWL% nke 10.1% maka ndị 45 nke ndị ọrịa 110 nwere data na 1 afọ, ma e jiri ya tụnyere ndị na-enweghị T2DM nke 16.7% maka 65 nke ndị ọrịa 110 nwere data na 1 afọ.
Pasent nke ndị ọrịa tụfuru ihe karịrị 5% nke ahụ ha bụ 82%, karịa 10% bụ 65%, karịa 15% bụ 41%, na ihe karịrị 20% bụ 21% na otu afọ.Ọgwụgwọ Semaglutide belatara nke ukwuu systolic na ọbara mgbali diastolic site na 6.8/2.5 mmHg;mkpokọta cholesterol site na 10.2 mg / dL;LDL nke 5.1 mg/dL;na triglycerides nke 17.6 mg / dl.Ọkara n'ime ndị ọrịa ahụ nwere mmetụta ndị metụtara iji ọgwụ eme ihe (154/305) nke a na-akọkarị bụ ọgbụgbọ (38%) na afọ ọsịsa (9%) (Figure 1D).Mmetụta ndị dị na ya na-abụkarị ndị dị nro na-adịghị emetụta àgwà ndụ mana na 16 ha kpatara ịkwụsị ọgwụ ahụ.
Ndị na-ede akwụkwọ kwubiri: "E jikọtara Semaglutide dị oke arọ na mmụba nke metabolic na 1 afọ na ọtụtụ saịtị n'ezie n'ụwa ọmụmụ, na-egosipụta irè ya na ọgwụgwọ nke oke ibu, na ndị ọrịa na-enweghị T2DM."
Ndị otu Mayo na-akwado ọtụtụ ihe odide ndị ọzọ metụtara semaglutide, gụnyere nsonaazụ dị arọ na ndị ọrịa nwere nlọghachi azụ mgbe ịwachara ahụ bariatric;Mbelata ịdị arọ nke ndị ọrịa nọ na ọgwụ ndị ọzọ na-egbochi oke ibu na mbụ ma e jiri ya tụnyere ndị na-adịghị.
Oge nzipu: Sep-20-2023